Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus BANCAP HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus BANCAP HC.
ABSTRAL vs BANCAP HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
BANCAP HC contains hydrocodone, a mu-opioid receptor agonist, and acetaminophen, which inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, to reduce pain and fever.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Each 5 mL contains hydrocodone bitartrate 5 mg and acetaminophen 500 mg. For moderate to moderately severe pain: 1 tablet (or 5 mL suspension) every 4 to 6 hours as needed; maximum single dose: 2 tablets (10 mL); maximum daily dose: 8 tablets (40 mL) due to acetaminophen limit.
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life: 3.8 hours (range 3.3–4.4 h) for hydrocodone; clinical context: requires dosing every 4–6 hours to maintain analgesic effect, with potential accumulation in renal impairment.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal elimination of unchanged drug and metabolites: 90% (60% as glucuronide conjugates, 10% as unchanged drug, 5% as cysteine and mercapturic acid conjugates); biliary/fecal: 5%; the remainder as other metabolites. Renal clearance of hydrocodone is dose-dependent.
Category C
Category C
Opioid Analgesic
Opioid Analgesic